NanoART, neuroAIDS and CNS drug delivery

Ari Nowacek, Howard E. Gendelman

Research output: Contribution to journalReview articlepeer-review

112 Scopus citations


A broad range of nanomedicines is being developed to improve drug delivery for CNS disorder. The structure of the blood-brain barrier (BBB), the presence of efflux pumps and the expression of metabolic enzymes pose hurdles for drug-brain entry. Nanoformulations can circumvent the BBB to improve CNS-directed drug delivery by affecting such pumps and enzymes. Alternatively, they can be optimized to affect their size, shape, and protein and tipid coatings to facilitate drug uptake, release and ingress across the barrier. This is important as the brain is a sanctuary for a broad range of pathogens including HIV-1. Improved drug delivery to the CNS would affect pharmacokinetic and drug biodistribution properties. This article focuses on how nanotechnology can serve to improve the delivery of antiretroviral medicines, termed nanoART, across the BBB and affect the biodistribution and clinical benefit for HIV-1 disease.

Original languageEnglish (US)
Pages (from-to)557-574
Number of pages18
Issue number5
StatePublished - 2009


  • BBB
  • CNS
  • Drug delivery
  • HIV
  • Nanoparticles
  • Nanotechnology

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • General Materials Science


Dive into the research topics of 'NanoART, neuroAIDS and CNS drug delivery'. Together they form a unique fingerprint.

Cite this